SARS-CoV-2 keeps changing. What does this mean for the treatment of COVID-19? By EKATERINA PESHEVA January 3, 2023 Research Harvard As the world enters year four of the COVID-19 pandemic, scientists have amassed a great deal of knowledge about the biology and behavior of SARS-CoV-2 and about the clinical features of the disease that it causes. They […]
Rajesh T. Gandhi, MD1; Preeti N. Malani, MD, MSJ2,3; Carlos del Rio, MD4, JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335 Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint summarizes currently available therapeutics for nonhospitalized patients in the setting of the Omicron variant including principles for equitable allocation. Patients with mild or moderate COVID-19 […]
Authors: Alicia Powe May 14, 2022 Gateway Pundit After two years of inundating the public with propaganda and fear surrounding COVID-19, the mainstream media and the federal government turned the page on the manufactured pandemic. While coronavirus fades from headlines, the number of people purportedly dying from the virus continues to climb. Over one million […]
Authors: By: Neesha C. Siriwardane & Rodney Shackelford, DO, Ph.D. April 15, 2020 Introduction to COVID-19 Coronaviruses are enveloped single-stranded RNA viruses of the Coronaviridae family and order Nidovirales (1). The viruses are named for their “crown” of club-shaped S glycoprotein spikes, which surround the viruses and mediate viral attachment to host cell membranes (1-3). Coronaviruses are found in domestic […]
Contributors BC, CW, and YeW had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CW and BC decided to publish the paper. BC, CW, YeW, PWH, TJ, and FGH provided input on the trial design. BC, CW, […]
Authors: By Ralph Ellis October 19, 2020 — A large study sponsored by the World Health Organization found that remdesivir doesn’t help hospitalized patients with COVID-19 survive and doesn’t even shorten the recovery time of those who do survive. These findings contradict smaller studies which found remdesivir, an antiviral drug, helped hospitalized coronavirus patients recover […]
Authors: NIAID Office of Communications Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by […]
Authors: By Jon Cohen, Kai KupferschmidtOct. 28, 2020 , 7:05 PM October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 […]
Authors: Beigel, et al. Remdesivir for the Treatment of COVID-19 – A Preliminary Report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2007764 (2020). What The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New England Journal of Medicine. The preliminary analysis is based […]
Authors: John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., et al., for the ACTT-1 Study Group Members* Abstract BACKGROUND Although several therapeutic agents have been […]
